In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome
Objective: To assess in vivo, with molecular imaging the brain distribution of tau aggregates ([18F]AV1451 PET) and β-amyloid depositions ([18F]AV45 PET) in patients with Corticobasal…Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease
Objective: To directly compare 18F-DOPA with a highly specific dopamine transporter radioligand 11C-PE2I, for the assessment of motor severity and rate of progression in Parkinson's…PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Objective: To evaluate change in AV-1451 positron emission tomography (PET) imaging in patients with Progressive Supranuclear Palsy (PSP) and Cortico-Basal Syndrome (CBS) over 9 months…18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease
Objective: To describe cortical and subcortical 18F-AV-1451 binding in Parkinson’s disease patients with and without mild cognitive impairment (PD-MCI and PD-nonMCI). Background: The radioligand 18F-AV-1451…Treatment of lipopolysaccharide-induced parkinsonism
Objective: This single case report of levodopa-responsive parkinsonism, caused by an accidental systemic contamination with 10 microgram lipopolysaccharides (LPS) from Salmonella minnesota, describes the treatment…THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy
Objective: The objective of our study is to investigate characteristics of THK-5351 binding in patients with clinically diagnosed progressive supranuclear palsy (PSP) and correlate tau-tracer…Staging of cognitive impairment: Validation of a novel cognitive score with [18F]FDG-PET
Objective: To provide insight into the nature of cognitive deterioration and Parkinson's disease dementia (PDD) and to validate a novel cognitive score (also submitted for…Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson’s disease
Objective: To evaluate the differences in striatal subregional dopamine transporter loss in Parkinson's disease (PD) and supranuclear palsy (PSP) and the diagnostic value of [18F]PR04.MZ…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- 35
- Next Page »